Kazia Therapeutics Limited (NASDAQ:KZIA) Short Interest Down 90.2% in February

Kazia Therapeutics Limited (NASDAQ:KZIA) was the recipient of a significant decrease in short interest in the month of February. As of February 15th, there was short interest totalling 90,500 shares, a decrease of 90.2% from the January 31st total of 921,900 shares. Based on an average trading volume of 1,770,000 shares, the short-interest ratio is presently 0.1 days. Approximately 3.1% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

Separately, Maxim Group began coverage on Kazia Therapeutics in a report on Thursday, February 6th. They issued a “buy” rating and a $3.00 price target on the stock.

Hedge Funds Weigh In On Kazia Therapeutics

An institutional investor recently bought a new position in Kazia Therapeutics stock. Barclays PLC bought a new stake in Kazia Therapeutics Limited (NASDAQ:KZIA) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 120,000 shares of the company’s stock, valued at approximately $212,000. Barclays PLC owned approximately 2.38% of Kazia Therapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 30.89% of the company’s stock.

Kazia Therapeutics Stock Performance

Shares of Kazia Therapeutics stock opened at $0.84 on Friday. Kazia Therapeutics has a twelve month low of $0.78 and a twelve month high of $15.80. The business has a 50-day moving average price of $1.58 and a 200-day moving average price of $3.43.

Kazia Therapeutics Company Profile

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company’s lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3.